We are steadfast in our mission that veterinary patients will receive the same innovative care as their beloved human companions. This license paves the way for changing the way cancer is treated in veterinary medicine and we intend to pair it with other modalities in our pipeline.
LEXINGTON, Ky. (PRWEB)
October 17, 2022
– This new license allows Ardent Animal Health to build on its current base of innovative therapies for canine cancer.
- This novel checkpoint inhibitor will be the first of its kind in Veterinary medicine for canine cancer.
- As the first company worldwide providing point-of-care regenerative cell therapies within veterinary clinics, Ardent Animal Health continues to expand the development of innovative and affordable solutions for canine cancer.
Ardent Animal Health, a Breakthru Investment Portfolio Company, has completed a license agreement for a novel checkpoint inhibitor cancer treatment for dogs. The treatment is designed to act as a catalyst for the current suite of cancer products in the Ardent pipeline.
An estimated fifty percent of dogs over the age of ten will develop cancer. Targeted cancer treatments for pets have lagged behind the human market, which is experiencing a breakthrough in the advent of novel immunotherapies for various cancers.
Ardent Animal Health develops novel biological treatments for aging-related and inflammatory diseases including cancer. To date Ardent has treated over 1,000 dogs with a novel customized cancer immunotherapy, K9-ACV, which is designed to teach the immune system that the patient’s cancer is a foreign invader, thus seeking out and destroying the disease from within. This experimental approach is now available at veterinary clinics across the United States.
The novel checkpoint inhibitor was developed by researchers from the University of Minnesota College of Medicine. The treatment has been successfully evaluated in dogs and is in development for human cancers. Ardent believes this approach will provide a path to affordable and broadly applicable cancer treatments, as well as strengthen its pipeline.
“Ardent and our partners thrive on assisting veterinarians with challenging diseases. Pet families seek out our referral partners due to this commitment,” says Thomas Masterson, President of Ardent Animal Health. “Cancer certainly presents a unique challenge not only from a scientific standpoint but also challenges us in veterinary medicine to align innovation with affordability. We are steadfast in our mission that veterinary patients will receive the same innovative care as their beloved human companions. This license paves the way for changing the way cancer is treated in veterinary medicine and we intend to pair it with other modalities in our pipeline.”
According to Mr. Masterson, Ardent Animal Health will continue to develop novel approaches for early disease detection and treatments, with a focus on precision medicine for pets in need.
“We will continue to focus much of our strategy to create novel products and services utilized in veterinary hospitals. Our belief is that this approach is key to the future of animal health. It is important not only for value creation but to ensure veterinarians can diagnose and treat their patients with the same leading-edge strategies underway in human health, our pets deserve it.”
Disclaimer
Experimental Cancer Vaccines created by Ardent Animal Health are provided under 9 CFR 103.3 via USDA Center for Veterinary Biologics oversight for use under supervision/prescription of a licensed veterinarian. Safety & efficacy have not been yet established.
About Ardent Animal Health
Ardent Animal Health is a veterinary biotechnology company based in Lexington, KY. Founded in 2016, the company provides training and advanced treatments to innovative veterinary practices around the world. Its pipeline includes novel cancer and stem cell treatments for veterinary patients. Ardent is a synonym for passionate, fiery, and committed which manifests through Ardent’s worldwide referral network providing advanced care for complicated diseases.
https://ardentanimalhealth.com/
About Breakthru Investments
Breakthru Investments based in Milwaukee, Wisconsin was founded by Jerry Jendusa and partners. The investment portfolio and entrepreneurial accelerator currently include a human and animal health portfolio of companies; Ardent Animal Health, Lexington, KY, Biocut Systems, Milwaukee, WI, Xiogenix, Milwaukee, WI, Vendura, Madison, WI and Shared Bio, Raleigh, North Carolina. Its mission is to aid in recovery by fostering innovation and growth through entrepreneurship.
Media Contact:
Matthew Yeich
859-885-7111
matt@ardentanimalhealth.com
Share article on social media or email: